Cell therapy for neuropathic pain in spinal cord injuries

Eaton, Mary J.

doi:10.1517/14712598.4.12.1861

Cited by 12 publications

(7 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent review discusses the potential of this approach for NeP associated with spinal cord injury [115]. However, a number of preclinical studies suggest that the utility of this approach may be extended to peripherally initiated NeP.…”

Section: Cell Therapymentioning

confidence: 99%

New targets for neuropathic pain therapeutics

Kinloch¹,

Cox²

2005

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

Neuropathic pain (NeP) is initiated by a lesion or dysfunction in the nervous system. Unlike physiological pain it serves no useful purpose and is usually sustained and chronic. NeP encompasses a wide range of pain syndromes of diverse aetiologies which together account for > 12 million sufferers in the US. Currently, there are a number of therapies available for NeP, including gabapentin, pregabalin, anticonvulsants (tiagabine HCl), tricyclic antidepressants (amitriptyline, nortriptyline) and acetaminophen/opioid combination products (Vicodin, Tylenol #3). However, these products do not provide sufficient pain relief and a significant proportion of sufferers are refractory (60%). Therefore, there is a need for new therapies that provide more predictable efficacy in all patients with improved tolerability. Over the last decade, understanding of the basic mechanisms contributing to the generation of NeP in preclinical animal models has greatly improved. Together with the completion of the various genome sequencing projects and significant advances in microarray and target validation strategies, new therapeutic approaches are being rigourously pursued. This article reviews the rationale behind a number of these mechanism-based approaches, briefly discusses specific challenges that they face, and finally, speculates on the potential of emerging technologies as alternative therapeutic strategies to the traditional 'small-molecule' approach.

show abstract

Section: Cell Therapymentioning

confidence: 99%

New targets for neuropathic pain therapeutics

Kinloch¹,

Cox²

2005

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

show abstract

“…Immortalized chromaffin cells are a possibility now suggested as source for antinociceptive agents. 8 Clinical transplantation of fully differentiated adrenomedullary chromaffin cells was disappointing, especially due to the low survival rate of the grafted cells. In addition, in the adult adrenal, the proportion of dopaminergic cells is low (1% of the cells); the vast majority of cells produces epinephrine and to a lesser extend norepinephrine.…”

mentioning

confidence: 99%

Is there a role for chromaffin progenitor cells in neurodegenerative diseases?

et al. 2008

View full text Add to dashboard Cite

“…It has been reported to be beneficial to functional recovery after SCI [25][26][27]. Original attempts at transplanting stem cells in the adult spinal cord have shown that the adult environment would trigger a massive differentiation of the surviving transplanted cells in the astrocytic phenotype, thus reinforcing the physical barrier formed by the scar [28].…”

Section: Cell Transplantationmentioning

confidence: 99%

Treatments for spinal cord injury: Is there hope in neurosteroids?

Compagnone

2008

The Journal of Steroid Biochemistry and Molecular Biology

View full text Add to dashboard Cite

Cell therapy for neuropathic pain in spinal cord injuries

Cited by 12 publications

References 77 publications

New targets for neuropathic pain therapeutics

New targets for neuropathic pain therapeutics

Is there a role for chromaffin progenitor cells in neurodegenerative diseases?

Treatments for spinal cord injury: Is there hope in neurosteroids?

Contact Info

Product

Resources

About